Cart
sales@molnova.com
2,4'-Dihydroxybenzophenone
CAS No. 606-12-2
2,4'-Dihydroxybenzophenone( —— )
Catalog No. M18881 CAS No. 606-12-2
2,4-dihydroxybenzophenone (BP-1) can effectively protect C57BL/6J mice from APAP-induced hepatotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 81 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2,4'-Dihydroxybenzophenone
-
NoteResearch use only, not for human use.
-
Brief Description2,4-dihydroxybenzophenone (BP-1) can effectively protect C57BL/6J mice from APAP-induced hepatotoxicity.
-
Description2,4-dihydroxybenzophenone (BP-1) can effectively protect C57BL/6J mice from APAP-induced hepatotoxicity. BP-1 has a protective effect on acute hepatotoxicity and neurotoxicity of mice induced by cocaine. Its mechanisms might be associated with its antioxidant activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetAdrenergic Receptor
-
RecptorAntioxidant
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number606-12-2
-
Formula Weight214.22
-
Molecular FormulaC13H10O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESc1ccc(c(c1)C(=O)c1ccc(cc1)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. He YY, et al. Protective effects of 2,4-dihydroxybenzophenone against acetaminophen-induced hepatotoxicity in mice. World J Gastroenterol. 2011 Jun 7;17(21):2663-6.
molnova catalog
related products
-
Terbutaline
Terbutaline is a short-acting agonist of β2-adrenergic receptor (β2-AR) . It is an active metabolite of bambuterol.
-
Brimonidine
Brimonidine is a drug used as eye drops under the brand names Alphagan and Alphagan-P. It is used to treat open-angle glaucoma or ocular hypertension
-
Dabuzalgron
Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.
